Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DOVATO - Health Canada Drug Approval Details

Approvals/Health Canada/DOVATO

Authorized

STANDARD

DOVATO

viiv healthcare ulc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: fc47be17e6e3dfa9
Company: viiv healthcare ulc
Type: Standard

Approval Details

Approval Id: fc47be17e6e3dfa9
Drug Approval Canada Name: DOVATO
Product Name: DOVATO
Status: Marketed
Status Date: 2019-09-09
Original Market Date: 2019-09-09
Din: 02491753
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 08:18.08.12
Atc Original: J05AR25 LAMIVUDINE AND DOLUTEGRAVIR
Atc Name: j 05 ar 25
Aig Number: 0261731001
Company Name: viiv healthcare ulc
Company Address: 1400, 75 Rue Queen, Montreal, Quebec, Canada, H3C 2N6

Active Ingredients

LAMIVUDINE

300 MG

DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)

50 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

fc47be17e6e3dfa9

Type

Standard

Back to Health Canada Approvals